What is Replicate Bioscience?
Replicate Bioscience is a pioneering biotechnology firm dedicated to the advancement of self-replicating RNA (srRNA) technology. Unlike traditional linear mRNA approaches, the company's proprietary platform utilizes srRNA vectors to achieve superior protein expression and enhanced therapeutic efficacy within cellular environments. This technological differentiation allows Replicate to address a broad spectrum of complex medical conditions, including infectious diseases, oncology, and autoimmune disorders. By optimizing the delivery and duration of therapeutic protein production, the company is effectively expanding the horizon for precision medicine and patient-centric treatment modalities.
How much funding has Replicate Bioscience raised?
Replicate Bioscience has raised a total of $46M across 2 funding rounds:
Angel/Seed
$6M
Series A
$40M
Angel/Seed (2021): $6M with participation from Apple Tree Partners
Series A (2021): $40M led by ATP
Key Investors in Replicate Bioscience
Apple Tree Partners
Apple Tree Partners is a prominent venture capital firm that operates ATP RD Labs, an incubator focused on foundational science, providing comprehensive preclinical pharmacology and molecular assay services to its portfolio companies.
ATP
ATP is a specialized life sciences investment firm that provides strategic capital and operational support to early-stage biotech companies developing transformative medical technologies.
What's next for Replicate Bioscience?
With the recent infusion of capital, Replicate Bioscience is poised to transition from its foundational research phase into more robust clinical validation. The strategic roadmap likely involves scaling its srRNA manufacturing capabilities and advancing its lead candidates through regulatory milestones. As the company continues to refine its vector technology, it remains focused on building a sustainable pipeline that addresses significant unmet medical needs. Future growth will likely be defined by the firm's ability to demonstrate clinical superiority in human trials, potentially attracting further institutional backing or strategic partnerships with established pharmaceutical entities looking to integrate advanced RNA therapeutics into their portfolios.
See full Replicate Bioscience company page
